Skye Bioscience, Inc.
SKYE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,357 | $14,338 | $7,197 | $7,793 |
| G&A Expenses | $3,907 | $3,906 | $4,562 | $4,554 |
| SG&A Expenses | $3,907 | $3,906 | $4,562 | $4,554 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1,681 |
| Operating Expenses | $13,265 | $18,244 | $11,760 | $10,666 |
| Operating Income | -$13,265 | -$18,244 | -$11,760 | -$10,666 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $510 | $622 | $658 | $920 |
| Pre-Tax Income | -$12,755 | -$17,621 | -$11,101 | -$9,746 |
| Tax Expense | $0 | $3 | $2 | $0 |
| Net Income | -$12,755 | -$17,625 | -$11,103 | -$9,746 |
| % Margin | – | – | – | – |
| EPS | -0.32 | -0.44 | -0.28 | -0.24 |
| % Growth | 27.3% | -57.1% | -16.7% | – |
| EPS Diluted | -0.32 | -0.44 | -0.28 | -0.24 |
| Weighted Avg Shares Out | 39,666 | 39,659 | 39,652 | 39,969 |
| Weighted Avg Shares Out Dil | 39,666 | 39,659 | 39,652 | 39,969 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $533 | $619 | $732 |
| Interest Expense | $0 | $0 | $1 | – |
| Depreciation & Amortization | $179 | $187 | $177 | $175 |
| EBITDA | -$12,576 | -$17,434 | -$10,922 | -$9,618 |
| % Margin | – | – | – | – |